Grifols one of the world's largest plasma product manufacturers and a pioneer
in the research and development of therapeutic alternatives designed to
contribute to both scientific and social development, has agreed a loan
for 100 million euros with the European Investment Bank (EIB) following
conclusion of financial and legal negotiations, including due
diligence.
Grifols will use the EIB loan to support its
investment in R&D, focusing primarily on the search for new
indications for plasma proteins, including the treatment of Alzheimer's
disease, vascular diseases, cardiovascular surgery and arterial
thrombosis, amongst others.
Grifols is one of the first European
companies to receive a loan from the new European Fund for Strategic
Investments (EFSI), also known as the Juncker Plan. This is an
initiative supported by the EIB and the European Commission, with the
aim of reactivating investment in strategic projects throughout Europe,
and its objectives include strengthening R&D in European companies.
Grifols hopes that its successful engagement with the EIB will
encourage other Spanish companies to consider this source of funding for
their projects.
